TGFBI and cancer: The LPS-positive group showed significantly greater cancer stromal TGFBI expression (p < 0.0001), more HER2-negative cases (p = 0.012), greater PD-L1 expression (p = 0.0029), increased wnt3a signaling (p = 0.0028) and lower E-cadherin expression (p = 0.0055) (EMT marker) than the LPS-positive group.